Biogen to Acquire Pfizer’s PF-05251749 to Bolster its Neurological Pipeline

 Biogen to Acquire Pfizer’s PF-05251749 to Bolster its Neurological Pipeline

Biogen to Acquire Pfizer’s PF-05251749 to Bolster its Neurological Pipeline

Shots:

  • Pfizer’s to receive $75M up front, $365M development & commercial milestones and royalties on sales of the product. Biogen plans to develop Pfizer’s PF-05251749 for Sundowning in AD and Irregular Sleep-Wake Rhythm Disorder (ISWRD) in PD
  • The acquisition of PF-05251749 complements Biogen’s existing pipeline therapies in AD & PD. The transaction is expected to be closed in Q1’20
  • PF-05251749 is a CNS-penetrant regulator of circadian rhythm with potential to address behavioral and neurological symptoms in neurological diseases with the expected initiation of P-Ib study in Q4’20

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: The Motley Fool

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post